# Triterpenoid CDDO-EA Protects from Hyperglycemia, Hyperinsulinemia, and Obesity by Decreasing Energy Intake

**Authors:** Austin E. Cantu, Cordelia Rasa, Shizue Mito, Denae Cantu, Juan Carlos Lopez-Alvarenga, Leslie L. Rivera-Lopez, Israel Rios, Ashley Abrego-Gonzalez, Sara M. Reyna

PMC · DOI: 10.3390/ijms26125485 · International Journal of Molecular Sciences · 2025-06-07

## TL;DR

The compound CDDO-EA helps reduce obesity and related diabetes symptoms in mice by lowering calorie intake and improving glucose and insulin levels.

## Contribution

The study reveals that CDDO-EA protects against obesity and hyperglycemia by decreasing energy intake and improving metabolic parameters.

## Key findings

- CDDO-EA prevents high-fat diet-induced obesity in mice.
- CDDO-EA reduces glucose and insulin levels in mice fed a high-fat diet.
- The protective effects of CDDO-EA are associated with decreased caloric intake.

## Abstract

Obesity is a significant factor in the development of type 2 diabetes (T2D). Treatment of obesity is pivotal in the prevention and management of T2D, and the development of new pharmacological therapies are studied for improving insulin resistance and glucose intolerance. Oleanolic acid-derived triterpenoids, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acids (CDDOs), are studied to elucidate the mechanisms by which they protect against obesity. However, fundamental knowledge gaps remain regarding the physiological and molecular mechanisms by which CDDOs protect against obesity. Our recently published studies showed that CDDO-ethyl amide (CDDO-EA) prevents skeletal muscle inflammation by inhibiting activation of nuclear factor-kappa B (NF-κB) signaling. Moreover, CDDO-EA induced translocation of glucose transporter 4, GLUT4, in skeletal muscle cells. We hypothesized that CDDO-EA protects from obesity-induced hyperglycemia in mice fed a high-fat diet (HFD). Our results show that CDDO-EA protects from HFD-induced obesity but has no effect on body weight in mice fed a low-fat diet (LFD). Our data show that CDDO-EA inhibition of weight gain is associated with reduced caloric intake and glucose and insulin levels in mice fed an HFD. This highlights the potential of CDDO-EA as a therapeutic agent for obesity treatment and the protection against the development of T2D.

## Linked entities

- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1), SLC2A4 (solute carrier family 2 member 4)
- **Chemicals:** CDDO-EA (PubChem CID 44159258), oleanolic acid (PubChem CID 10494)
- **Diseases:** type 2 diabetes (MONDO:0005148), obesity (MONDO:0011122)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Slc2a4 (solute carrier family 2 (facilitated glucose transporter), member 4) [NCBI Gene 20528] {aka GT2, Glut-4, Glut4, twgy}
- **Diseases:** glucose intolerance (MESH:D018149), Hyperglycemia (MESH:D006943), inflammation (MESH:D007249), weight gain (MESH:D015430), T2D (MESH:D003924), Hyperinsulinemia (MESH:D006946), Obesity (MESH:D009765), insulin resistance (MESH:D007333)
- **Chemicals:** 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acids (MESH:C116817), Triterpenoid (MESH:D014315), fat (MESH:D005223), Oleanolic acid (MESH:D009828), CDDO-EA (-), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12193413/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12193413/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12193413/full.md

---
Source: https://tomesphere.com/paper/PMC12193413